Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on one-time curative genetic therapies, has announced its participation in several upcoming investor conferences in September 2024. These include:
1. Morgan Stanley Global Healthcare Conference on September 4 in New York
2. Wells Fargo Healthcare Conference on September 5 in Boston
3. Cantor Global Healthcare Conference on September 17 in New York
4. Chardan's Genetic Medicines Conference on September 30 in New York
The company will engage in fireside chats, panel discussions, and investor meetings during these events. Live audio webcasts of the presentations will be available on Prime Medicine's website, with replays accessible for 90 days after each event.
Prime Medicine (Nasdaq: PRME), un'azienda biotecnologica focalizzata su terapie genetiche curative una tantum, ha annunciato la sua partecipazione a diverse conferenze per investitori in programma a settembre 2024. Queste includono:
1. Conferenza Globale sulla Sanità di Morgan Stanley il 4 settembre a New York
2. Conferenza sulla Sanità di Wells Fargo il 5 settembre a Boston
3. Conferenza Globale sulla Sanità di Cantor il 17 settembre a New York
4. Conferenza sulle Medicine Genetiche di Chardan il 30 settembre a New York
L'azienda parteciperà a discussioni informali, tavole rotonde e incontri con gli investitori durante questi eventi. I webcast audio dal vivo delle presentazioni saranno disponibili sul sito web di Prime Medicine, con repliche accessibili per 90 giorni dopo ciascun evento.
Prime Medicine (Nasdaq: PRME), una empresa biotecnológica centrada en terapias genéticas curativas de una sola vez, ha anunciado su participación en varias conferencias de inversores que se llevarán a cabo en septiembre de 2024. Estas incluyen:
1. Conferencia Global de Salud de Morgan Stanley el 4 de septiembre en Nueva York
2. Conferencia de Salud de Wells Fargo el 5 de septiembre en Boston
3. Conferencia Global de Salud de Cantor el 17 de septiembre en Nueva York
4. Conferencia de Medicinas Genéticas de Chardan el 30 de septiembre en Nueva York
La empresa participará en charlas informales, paneles de discusión y reuniones con inversores durante estos eventos. Los webcasts de audio en vivo de las presentaciones estarán disponibles en el sitio web de Prime Medicine, con repeticiones accesibles por 90 días después de cada evento.
프라임 메디슨 (Nasdaq: PRME)은 일회성 치유 유전자 치료에 중점을 둔 생명공학 기업으로, 2024년 9월에 예정된 몇 가지 투자자 컨퍼런스에 참여한다고 발표했습니다. 포함되는 행사들은 다음과 같습니다:
1. 모건 스탠리 글로벌 헬스케어 컨퍼런스 9월 4일 뉴욕에서
2. 웰스파고 헬스케어 컨퍼런스 9월 5일 보스턴에서
3. 칸토 글로벌 헬스케어 컨퍼런스 9월 17일 뉴욕에서
4. 차르단의 유전자 의약품 컨퍼런스 9월 30일 뉴욕에서
회사는 이 행사들에서 캠프파이어 채팅, 패널 토론 및 투자자 회의에 참여할 예정입니다. 라이브 오디오 웹캐스트는 프라임 메디슨의 웹사이트에서 제공되며, 각 행사 후 90일 동안 다시 볼 수 있습니다.
Prime Medicine (Nasdaq: PRME), une entreprise biopharmaceutique axée sur des thérapies géniques curatives à dose unique, a annoncé sa participation à plusieurs conférences pour investisseurs prévues en septembre 2024. Celles-ci incluent :
1. Conférence Mondiale sur la Santé de Morgan Stanley le 4 septembre à New York
2. Conférence sur la Santé de Wells Fargo le 5 septembre à Boston
3. Conférence Mondiale sur la Santé de Cantor le 17 septembre à New York
4. Conférence sur les Médicaments Génétiques de Chardan le 30 septembre à New York
L'entreprise participera à des discussions informelles, des tables rondes et des réunions avec des investisseurs lors de ces événements. Des webcasts audio en direct des présentations seront disponibles sur le site Web de Prime Medicine, avec des rediffusions accessibles pendant 90 jours après chaque événement.
Prime Medicine (Nasdaq: PRME), ein biopharmazeutisches Unternehmen, das sich auf einmalige kurative Gentherapien spezialisiert hat, hat seine Teilnahme an mehreren bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. Diese umfassen:
1. Morgan Stanley Globale Gesundheitskonferenz am 4. September in New York
2. Wells Fargo Gesundheitskonferenz am 5. September in Boston
3. Cantor Globale Gesundheitskonferenz am 17. September in New York
4. Chardan Konferenz für genetische Medikamente am 30. September in New York
Das Unternehmen wird während dieser Veranstaltungen an informellen Gesprächen, Diskussionsrunden und Investorenmeetings teilnehmen. Live-Audio-Webcasts der Präsentationen werden auf der Website von Prime Medicine verfügbar sein, mit Wiederholungen, die 90 Tage nach jeder Veranstaltung zugänglich sind.
- None.
- None.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 1:05 p.m. ET in New York, NY.
- Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 11:00 a.m. ET in Boston, MA.
- Cantor Global Healthcare Conference: Company management will host 1x1 investor meetings on Tuesday, September 17, 2024, in New York, NY.
- Chardan’s 8th Annual Genetic Medicines Conference: Fireside chat at 1:30 p.m. ET and panel discussion, “Gene Insertion and Gene Correction,” at 5:40 p.m. ET on Monday, September 30, 2024, in New York, NY.
Live audio webcasts of each presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. Replays of each webcast will be available on the Prime Medicine website for 90 days following the event.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around core areas of focus: hematology and immunology, liver, lung, ocular and neuromuscular. Across each core area, Prime Medicine’s initial focus is on genetic diseases with a fast, direct path to treating patients, and those with high unmet need not currently addressable using other gene editing approaches. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential to expand beyond the genetic diseases in its initial pipeline, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor Contact
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com
FAQ
What investor conferences will Prime Medicine (PRME) attend in September 2024?
When and where is Prime Medicine's (PRME) fireside chat at the Morgan Stanley conference?
Will Prime Medicine (PRME) participate in any panel discussions during these conferences?
How can investors access Prime Medicine's (PRME) conference presentations?
